Zomedica Corp. (ZOM)
| Market Cap | 171.98M |
| Revenue (ttm) | 25.97M |
| Net Income (ttm) | -36.77M |
| Shares Out | 979.95M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,367,863 |
| Open | 0.191 |
| Previous Close | 0.184 |
| Day's Range | 0.169 - 0.193 |
| 52-Week Range | 0.120 - 0.245 |
| Beta | 0.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 9, 2024 |
About ZOM
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line... [Read more]
Financial Performance
In 2023, Zomedica's revenue was $25.19 million, an increase of 33.05% compared to the previous year's $18.93 million. Losses were -$33.64 million, 88.3% more than in 2022.
Financial StatementsNews
Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA(R) Platform
OTA capability enhances introduction of new assays from rapidly expanding menu ANN ARBOR, MI / ACCESSWIRE / May 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinar...
Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity
Performance Sets New Record for First Quarter Revenue ANN ARBOR, MI / ACCESSWIRE / May 9, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering ...
Zomedica to Present at the EF Hutton Annual Global Conference on May 15, 2024
ANN ARBOR, MI / ACCESSWIRE / May 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for...
Zomedica Expands International Reach with CE Certification for VetGuardian(R) System
Key approval paves way for European expansion, tapping into a $4 billion vet services market ANN ARBOR, MI / ACCESSWIRE / May 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company")...
Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform
Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR, MI / ACCESSWIRE / May 2, 2024 / Zomedica Corp. (N...
Zomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / April 30, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products f...
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024
ANN ARBOR, MI / ACCESSWIRE / April 9, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device prod...
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device prod...
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / March 20, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products f...
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
ANN ARBOR, MI / ACCESSWIRE / March 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products ...
Zomedica Provides NYSE American Listing Update
ANN ARBOR, MI / ACCESSWIRE / March 13, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products ...
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
ANN ARBOR, MI / ACCESSWIRE / March 12, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products f...
Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs
ANN ARBOR, MI / ACCESSWIRE / March 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products f...
Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024
ANN ARBOR, MI / ACCESSWIRE / March 5, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products f...
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
ANN ARBOR, MI / ACCESSWIRE / February 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products...
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)
ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products...
Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products...
Open Letter to Zomedica Shareholders from your Chief Executive Officer
ANN ARBOR, MI / ACCESSWIRE / January 31, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic product...
Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference
ANN ARBOR, MI / ACCESSWIRE / January 30, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic product...
Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote "FOR" Proposed Reverse Stock Split
ANN ARBOR, MI / ACCESSWIRE / January 25, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic product...
Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split")
ANN ARBOR, MI / ACCESSWIRE / January 17, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic product...
Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position, and Discuss the Proposed Reverse Stock Split; Provides Notice of Special Virtual-Only Meeting of Shareholders on February 28, 2024
ANN ARBOR, MI / ACCESSWIRE / January 10, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products...
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
ANN ARBOR, MI / ACCESSWIRE / January 4, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products...
Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease
ANN ARBOR, MI / ACCESSWIRE / December 18, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic produc...
Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners
ANN ARBOR, MI / ACCESSWIRE / December 6, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic product...